{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T08:41:55Z","timestamp":1783586515262,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Israel Innovation Authority - Bio Convergence"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains a serious threat to health, with limited effective therapeutic options, especially due to advanced stage at diagnosis and its inherent resistance to chemotherapy, making it one of the leading causes of cancer-related deaths worldwide. The lack of clear treatment directions underscores the urgent need for innovative approaches to address and manage this deadly condition. In this research, we repurpose drugs with potential anti-cancer activity using machine learning (ML).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We tackle the problem by using a neural network trained on drug\u2013target interaction information enriched with drug\u2013drug interaction information, which has not been used for anti-cancer drug repurposing before. We focus on eravacycline, an antibacterial drug, which was selected and evaluated to assess its anti-cancer effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eravacycline significantly inhibited the proliferation and migration of BxPC-3 cells and induced apoptosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our study highlights the potential of drug repurposing for cancer treatment using ML. Eravacycline showed promising results in inhibiting cancer cell proliferation, migration and inducing apoptosis in PDAC. These findings demonstrate that our developed ML drug repurposing models can be applied to a wide range of new oncology therapeutics, to identify potential anti-cancer agents. This highlights the potential and presents a promising approach for identifying new therapeutic options.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bib\/bbae108","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T08:40:01Z","timestamp":1713775201000},"source":"Crossref","is-referenced-by-count":10,"title":["Eravacycline, an antibacterial drug, repurposed for pancreatic cancer therapy: insights from a molecular-based deep learning model"],"prefix":"10.1093","volume":"25","author":[{"given":"Adi","family":"Jabarin","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev (BGU) , P.O.B. 653, Beer-Sheva 8410501 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0647-8753","authenticated-orcid":false,"given":"Guy","family":"Shtar","sequence":"additional","affiliation":[{"name":"Department of Information Systems and Software Engineering, Ben-Gurion University of the Negev , P.O.B. 653, Beer-Sheva 8410501 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Feinshtein","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev (BGU) , P.O.B. 653, Beer-Sheva 8410501 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Mazuz","sequence":"additional","affiliation":[{"name":"Department of Information Systems and Software Engineering, Ben-Gurion University of the Negev , P.O.B. 653, Beer-Sheva 8410501 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bracha","family":"Shapira","sequence":"additional","affiliation":[{"name":"Department of Information Systems and Software Engineering, Ben-Gurion University of the Negev , P.O.B. 653, Beer-Sheva 8410501 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Ben-Shabat","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev (BGU) , P.O.B. 653, Beer-Sheva 8410501 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Rokach","sequence":"additional","affiliation":[{"name":"Department of Information Systems and Software Engineering, Ben-Gurion University of the Negev , P.O.B. 653, Beer-Sheva 8410501 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,21]]},"reference":[{"key":"2024042208395049500_ref1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","article-title":"Molecular subtypes of pancreatic cancer","volume":"16","author":"Collisson","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024042208395049500_ref2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"2024042208395049500_ref3","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20200401","article-title":"Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels","volume":"40","author":"Du","year":"2020","journal-title":"Biosci Rep"},{"key":"2024042208395049500_ref4","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"2024042208395049500_ref5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","article-title":"Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy","volume":"12","author":"Sarantis","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"2024042208395049500_ref6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2024042208395049500_ref7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat Cancer"},{"key":"2024042208395049500_ref8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10822-021-00430-5","article-title":"Best practices for repurposing studies","volume":"35","author":"Lewis","year":"2021","journal-title":"J Comput Aided Mol Des"},{"key":"2024042208395049500_ref9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cell.2020.01.021","article-title":"A deep learning approach to antibiotic discovery","volume":"180","author":"Stokes","year":"2020","journal-title":"Cell"},{"key":"2024042208395049500_ref10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.omto.2020.08.019","article-title":"Repurposing pimavanserin, an anti-Parkinson drug for pancreatic cancer therapy","volume":"19","author":"Ramachandran","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"2024042208395049500_ref11","doi-asserted-by":"crossref","DOI":"10.3390\/ph11020057","article-title":"Changing trends in computational drug repositioning","volume":"11","author":"Yella","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024042208395049500_ref12","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1021\/acs.jcim.9b00237","article-title":"Analyzing learned molecular representations for property prediction","volume":"59","author":"Yang","year":"2019","journal-title":"J Chem Inf Model"},{"key":"2024042208395049500_ref13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol Mol Biol Rev"},{"key":"2024042208395049500_ref14","doi-asserted-by":"crossref","first-page":"C539","DOI":"10.1152\/ajpcell.00047.2010","article-title":"Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature","volume":"299","author":"Griffin","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"2024042208395049500_ref15","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1111\/jcmm.15086","article-title":"Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down-regulating CCNE2 in pancreatic ductal adenocarcinoma","volume":"24","author":"Yang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"2024042208395049500_ref16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3343\/alm.2020.40.1.15","article-title":"Development of tigecycline resistance in carbapenemase-producing Klebsiella pneumoniae sequence type 147 via AcrAB overproduction mediated by replacement of the ramA promoter","volume":"40","author":"Yoon","year":"2020","journal-title":"Ann Lab Med"},{"key":"2024042208395049500_ref17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01326-19","article-title":"Novel plasmid-mediated tet(X5) gene conferring resistance to tigecycline, eravacycline, and omadacycline in a clinical Acinetobacter baumannii isolate","volume":"64","author":"Wang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024042208395049500_ref18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/bjc.2015.465","article-title":"Epidemiologic studies of the human microbiome and cancer","volume":"114","author":"Vogtmann","year":"2016","journal-title":"Br J Cancer"},{"key":"2024042208395049500_ref19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10096-016-2881-8","article-title":"Gut microbiota and colorectal cancer","volume":"36","author":"Gao","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024042208395049500_ref20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.aaa4972","article-title":"Cancer and the microbiota","volume":"348","author":"Garrett","year":"2015","journal-title":"Science"},{"key":"2024042208395049500_ref21","doi-asserted-by":"crossref","first-page":"e0219796","DOI":"10.1371\/journal.pone.0219796","article-title":"Detecting drug-drug interactions using artificial neural networks and classic graph similarity measures","volume":"14","author":"Shtar","year":"2019","journal-title":"PloS One"},{"key":"2024042208395049500_ref22","article-title":"ChemBERTa: large-scale self-supervised pretraining for molecular property prediction","author":"Chithrananda","year":"2020"},{"key":"2024042208395049500_ref23","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18042121","article-title":"A review on human-AI interaction in machine learning and insights for medical applications","volume":"18","author":"Maadi","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2024042208395049500_ref24","first-page":"2579","article-title":"Visualizing data using t-SNE","volume":"9","author":"Maaten","year":"2008","journal-title":"J Mach Learn Res"},{"key":"2024042208395049500_ref25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020831","article-title":"The anticancer potential of doxycycline and minocycline-a comparative study on amelanotic melanoma cell lines","volume":"23","author":"Rok","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024042208395049500_ref26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.canlet.2005.02.013","article-title":"Anticancer effects of fenretinide in human medulloblastoma","volume":"231","author":"Damodar Reddy","year":"2006","journal-title":"Cancer Lett"},{"key":"2024042208395049500_ref27","first-page":"572","article-title":"Trofosfamide in the palliative treatment of cancer: a review of the literature","volume":"27","author":"Latz","year":"2004","journal-title":"Onkologie"},{"key":"2024042208395049500_ref28","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/17460441.2021.1883585","article-title":"Artificial intelligence, machine learning, and drug repurposing in cancer","volume":"16","author":"Tanoli","year":"2021","journal-title":"Expert Opin Drug Discovery"},{"key":"2024042208395049500_ref29","doi-asserted-by":"crossref","first-page":"e114457","DOI":"10.1371\/journal.pone.0114457","article-title":"Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cells","volume":"9","author":"Song","year":"2014","journal-title":"PloS One"},{"key":"2024042208395049500_ref30","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1080\/14737140.2021.1991316","article-title":"Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy","volume":"21","author":"Sohail","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"2024042208395049500_ref31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"2024042208395049500_ref32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics1010001","article-title":"Classification framework and chemical biology of tetracycline-structure-based drugs","volume":"1","author":"Fuoco","year":"2012","journal-title":"Antibiotics (Basel)"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/25\/3\/bbae108\/57295445\/bbae108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/25\/3\/bbae108\/57295445\/bbae108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T08:40:23Z","timestamp":1713775223000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbae108\/7655596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbae108","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,3,27]]},"article-number":"bbae108"}}